大消息，“逆周期调节”，来了

Core Viewpoint - The regulatory body is implementing a counter-cyclical adjustment mechanism for fund product approvals to better protect investor interests, emphasizing a cautious approach towards new equity fund approvals amid high valuation benchmarks [1][2][7]. Fund Approval and Market Conditions - Regulatory scrutiny on new equity funds has increased, requiring that the performance benchmark index's rolling valuation over the last five years be below the 90th percentile and the last three months below the 80th percentile [2][3]. - Despite a bullish A-share market, fund companies are exercising restraint in launching new equity funds, with many setting initial fundraising caps at 2 billion to 3 billion yuan [1][4]. Fund Product Trends - Recent approvals have favored funds in sectors with relatively low valuations, such as healthcare, food, and consumer electronics, indicating a strategic focus on value [3][4]. - The approval of 16 hard technology products in mid-November reflects the regulatory body's timely response to market fluctuations, showcasing the effectiveness of the counter-cyclical adjustment mechanism [3][7]. Scale Management and Investor Experience - Fund companies are actively controlling the scale of new products, with many setting fundraising limits between 2 billion and 3 billion yuan, contrasting with the past trend of large-scale fund launches [4][5]. - Over 100 equity funds have announced restrictions on large subscriptions, with a focus on protecting existing investors and maintaining stable fund operations [5][6]. Regulatory Changes and Industry Transformation - The regulatory framework is shifting from a focus on scale to quality, with new performance evaluation metrics emphasizing long-term investment returns and investor experience [6][7]. - The implementation of counter-cyclical adjustment mechanisms is expected to enhance the capital market's resource allocation and support long-term investment strategies [7].